Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single Arm, Prospective Phase II Clinical Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy

NCT05979220 is registered in ClinicalTrials.gov with Shuangyue Liu as lead sponsor.

NCT NCT05979220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05979220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single Arm, Prospective Phase II Clinical Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
Lead sponsor
Shuangyue Liu
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2023
Completion date
June 30, 2028
Enrollment
178 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer